• Product nameAnti-Ras antibody
    See all Ras primary antibodies
  • Description
    Rabbit polyclonal to Ras
  • Tested applicationsSuitable for: ICC/IF, WBmore details
  • Species reactivity
    Reacts with: Mouse, Rat, Cow, Human
  • Immunogen

    Synthetic peptide derived from sequence near the effector binding loop (L2) of human Ras; sequence is identical to yeast, slime mold, fungi, Xenopus, chicken, rat and mouse.

  • Positive control
    • rat brain tissue extract. IF/ICC: MCF7 cell line.



Our Abpromise guarantee covers the use of ab69747 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

Application Abreviews Notes
  • Application notesWB: Use at a concentration of 1.0 µg/ml. Detects bands of approximately 19 and 21 kDa (predicted molecular weight: 21 and 23 kDa).

    Not yet tested in other applications.
    Optimal dilutions/concentrations should be determined by the end user.
  • Target

    • FunctionRas proteins bind GDP/GTP and possess intrinsic GTPase activity.
    • Involvement in diseaseDefects in HRAS are the cause of faciocutaneoskeletal syndrome (FCSS) [MIM:218040]. A rare condition characterized by prenatally increased growth, postnatal growth deficiency, mental retardation, distinctive facial appearance, cardiovascular abnormalities (typically pulmonic stenosis, hypertrophic cardiomyopathy and/or atrial tachycardia), tumor predisposition, skin and musculoskeletal abnormalities.
      Defects in HRAS are the cause of congenital myopathy with excess of muscle spindles (CMEMS) [MIM:218040]. CMEMS is a variant of Costello syndrome.
      Defects in HRAS may be a cause of susceptibility to Hurthle cell thyroid carcinoma (HCTC) [MIM:607464]. Hurthle cell thyroid carcinoma accounts for approximately 3% of all thyroid cancers. Although they are classified as variants of follicular neoplasms, they are more often multifocal and somewhat more aggressive and are less likely to take up iodine than are other follicular neoplasms.
      Note=Mutations which change positions 12, 13 or 61 activate the potential of HRAS to transform cultured cells and are implicated in a variety of human tumors.
      Defects in HRAS are a cause of susceptibility to bladder cancer (BLC) [MIM:109800]. A malignancy originating in tissues of the urinary bladder. It often presents with multiple tumors appearing at different times and at different sites in the bladder. Most bladder cancers are transitional cell carcinomas. They begin in cells that normally make up the inner lining of the bladder. Other types of bladder cancer include squamous cell carcinoma (cancer that begins in thin, flat cells) and adenocarcinoma (cancer that begins in cells that make and release mucus and other fluids). Bladder cancer is a complex disorder with both genetic and environmental influences.
      Note=Defects in HRAS are the cause of oral squamous cell carcinoma (OSCC).
    • Sequence similaritiesBelongs to the small GTPase superfamily. Ras family.
    • Post-translational
      Palmitoylated by the ZDHHC9-GOLGA7 complex. A continuous cycle of de- and re-palmitoylation regulates rapid exchange between plasma membrane and Golgi.
      S-nitrosylated; critical for redox regulation. Important for stimulating guanine nucleotide exchange. No structural perturbation on nitrosylation.
    • Cellular localizationCell membrane. Golgi apparatus membrane. The active GTP-bound form is localized most strongly to membranes than the inactive GDP-bound form (By similarity). Shuttles between the plasma membrane and the Golgi apparatus.
    • Information by UniProt
    • Database links
    • Alternative names
      • C-BAS/HAS antibody
      • c-H-ras antibody
      • C-HA-RAS1 antibody
      • CTLO antibody
      • GTPase HRas antibody
      • GTPase KRas antibody
      • GTPase NRas antibody
      • H-Ras-1 antibody
      • H-RASIDX antibody
      • Ha-Ras antibody
      • HAMSV antibody
      • HRAS antibody
      • HRAS1 antibody
      • K RAS2A antibody
      • K RAS2B antibody
      • K RAS4A antibody
      • K RAS4B antibody
      • K-RAS antibody
      • KRAS antibody
      • KRAS1 antibody
      • KRAS2 antibody
      • N-RAS antibody
      • N-terminally processed antibody
      • NRAS antibody
      • NRAS1 antibody
      • p21ras antibody
      • RASH_HUMAN antibody
      • RASH1 antibody
      • RASK2 antibody
      • Transforming protein p21 antibody
      • v Ha ras Harvey rat sarcoma viral oncogene homolog antibody
      • v Ki ras2 Kirsten rat sarcoma viral oncogene homolog antibody
      • v ras neuroblastoma RAS viral oncogene homolog antibody
      see all

    Anti-Ras antibody images

    • ICC/IF image of ab69747 stained MCF7 cells. The cells were 4% formaldehyde fixed (10 min) and then incubated in 1%BSA / 10% normal goat serum / 0.3M glycine in 0.1% PBS-Tween for 1h to permeabilise the cells and block non-specific protein-protein interactions. The cells were then incubated with the antibody (ab69747, 5µg/ml) overnight at +4°C. The secondary antibody (green) was ab96899, DyLight® 488 goat anti-rabbit IgG (H+L) used at a 1/250 dilution for 1h. Alexa Fluor® 594 WGA was used to label plasma membranes (red) at a 1/200 dilution for 1h. DAPI was used to stain the cell nuclei (blue) at a concentration of 1.43µM.

    • Anti-Ras antibody (ab69747) at 1 µg/ml + rat brain tissue lysate

      Predicted band size : 21 , 23 kDa
      Observed band size : 19,21 kDa (why is the actual band size different from the predicted?)

    References for Anti-Ras antibody (ab69747)

    ab69747 has not yet been referenced specifically in any publications.

    Product Wall

    There are currently no Abreviews or Questions for ab69747.
    Please use the links above to contact us or submit feedback about this product.